EUVIMEDEUVIMED entdecken
Fallbericht

Congenital Hypodysfibrinogenemia due to γ326Cys→Tyr Mutation: Third Ever-Described Case Associated with Recurrent Venous Thrombosis and COVID Vaccine

Kumanan Rune Nanthan, Inge Søkilde Pedersen, Dorte Terp Andersen, Mustafa Vakur Bor

Acta Haematologica · 2024

DOI: 10.1159/000536562 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Haematologica, 2024. Verfasst von Kumanan Rune Nanthan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark, kumanan.nanthan@gmail.com. Hauptthemen laut MEDLINE: Venous Thrombosis, Afibrinogenemia, Fibrinogen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Congenital fibrinogen disorders are a heterogenous group of fibrinogen defects. Case Presentation: Here, we describe hypodysfibrinogenemia in a 33-year-old female patient with provoked recurrent deep vein thrombosis (DVT) diagnosed based on decreased functional and antigenic fibrinogen levels with a decreased functional/antigenic fibrinogen ratio. Definitive diagnosis of congenital hypodysfibrinogenemia is done by genotyping using whole-exome sequencing, which identified the γ326Cys→Tyr mutation combined with single-nucleotide polymorphisms: rs2070011 and rs2070018 in FGA and rs1049636 in FGG. Fibrin structure assays showed reduced maximum polymerization rate. The mother of the proband shares the same γ326Cys→Tyr mutation and experienced a provoked DVT.

Conclusion

Our case with DVT is the third ever-described occurrence of the mutation γ326Cys→Tyr that is associated with hypodysfibrinogenemia. The mechanism by which this mutation induces thrombosis remains unknown. Due to the high recurrence risk of thrombosis, the patient was treated with long-term reduced dose of rivaroxaban (10 mg daily) as secondary prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThrombosisAfibrinogenemiaFibrinogenHumansFemaleAdultMutationRecurrencePolymorphism, Single NucleotideFibrinogens, AbnormalRivaroxabanAmino Acid Substitution

Stichwörter der Autor:innen

Congenital fibrinogen disorderHypodysfibrinogenemiaThrombosisγ chain

Substanzen

FibrinogenFibrinogens, AbnormalFGG protein, humanFGA protein, humanRivaroxaban

Autor:innen und Institutionen

  • Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark, kumanan.nanthan@gmail.com.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, kumanan.nanthan@gmail.com.
  • Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Molecularbiology, University Hospital of Southern Denmark, Esbjerg, Denmark.
  • Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark.
  • Unit for Thrombosis Research, Department of Regional Health Research, Denmark, University of Southern Denmark, Esbjerg, Denmark.

Zitieren

APA

Nanthan, K. R., Pedersen, I. S., Andersen, D. T., & Bor, M. V. (2024). Congenital Hypodysfibrinogenemia due to γ326Cys→Tyr Mutation: Third Ever-Described Case Associated with Recurrent Venous Thrombosis and COVID Vaccine. Acta Haematologica. https://doi.org/10.1159/000536562

Vancouver

Nanthan KR, Pedersen IS, Andersen DT, Bor MV. Congenital Hypodysfibrinogenemia due to γ326Cys→Tyr Mutation: Third Ever-Described Case Associated with Recurrent Venous Thrombosis and COVID Vaccine. Acta Haematologica. 2024. doi:10.1159/000536562

BibTeX
@article{Nanthan2024,
  author = {Nanthan, Kumanan Rune and Pedersen, Inge Søkilde and Andersen, Dorte Terp and Bor, Mustafa Vakur},
  title = {Congenital Hypodysfibrinogenemia due to γ326Cys→Tyr Mutation: Third Ever-Described Case Associated with Recurrent Venous Thrombosis and COVID Vaccine},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000536562}
}
Kostenlos starten →